KOL Event on Oral APX3330 for Diabetic Retinopathy and Diabetic Macular Edema
Please join us on October 14th, 2022, 11 AM – 12:00 PM ET for a Key Opinion Leader (KOL) Webinar with Ocuphire Pharma, featuring Peter Kaiser, MD (Cleveland Clinic), Caroline Baumal, MD (Tufts Medical Center), and David Lally, MD (NEW ENGLAND RETINA CONSULTANTS, PC). KOL presentations will lead a discussion on Ocuphire’s APX3330, a novel, first-in-class oral tablet currently in Phase 2b Diabetic Retinopathy and Diabetic Macular Edema. The event will focus on the current treatment landscape and design of the Phase 2b trial, which is expected to read out by the end of 2022. A live Q&A session will follow.